NDA 208254 · Alcon Labs INC
Rhopressa
Netarsudil Mesylate · Ophthalmic
NovelLast checked: Nov 20, 2026Latest source record: Sep 18, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Dec 18, 2017
Approved uses
1
Original approval plus efficacy supplements
Registered trials
43
14 Phase 3, 8 recruiting
FAERS reports
1,971
434 serious, 63 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 20, 2026.
RHOPRESSA is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. RHOPRESSA ® is a Rho kinase inhibitor indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. ( 1 )
Mechanism: Netarsudil is a rho kinase inhibitor, which is believed to reduce IOP by increasing the outflow of aqueous humor through the trabecular meshwork. The exact mechanism is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- RHOPRESSA · NETARSUDIL MESYLATE EQ 0.02% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Netarsudil" as an intervention, any sponsor and status, largest first.
- Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular HypertensionPivotal-lookingCompleted
Aerie PharmaceuticalsIndustry
NCT02207621 · 756 participants · Start Jul 2014 · Primary completion Mar 2016
Drug: AR-13324 Ophthalmic Solution 0.02%; Timolol maleate Ophthalmic Solution 0.5% BID and 1 more · For: Ocular Hypertension; Open-angle Glaucoma
Sites: Bedminster, New Jersey
- Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Aerie PharmaceuticalsIndustry
NCT02674854 · 750 participants · Start Feb 2016 · Primary completion Mar 2017
Drug: PG324 Ophthalmic Solution 0.02%/0.005%; Netarsudil (AR-13324) ophthalmic solution 0.02% and 1 more · For: Open-angle Glaucoma; Ocular Hypertension
Sites: Bedminster, New Jersey
- Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Aerie PharmaceuticalsIndustry
NCT02558400 · 718 participants · Start Sep 18, 2015 · Primary completion May 17, 2017
Drug: PG324 Ophthalmic Solution 0.02%/0.005%; Netarsudil (AR-13324) Ophthalmic Solution 0.02% and 1 more · For: Open-angle Glaucoma; Ocular Hypertension
Sites: Bedminster, New Jersey
- Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Aerie PharmaceuticalsIndustry
NCT02558374 · 708 participants · Start Sep 2015 · Primary completion Dec 2016
Drug: AR-13324 Ophthalmic Solution 0.02%; Timolol Maleate Ophthalmic Solution 0.5% BID · For: Open-angle Glaucoma; Ocular Hypertension
Sites: Bedminster, New Jersey
- Next Generation RocklatanPivotal-lookingCompleted
Alcon ResearchIndustry
NCT06441643 · 646 participants · Start Sep 4, 2024 · Primary completion Nov 14, 2025
Drug: AR-17043 Ophthalmic Solution; PG043 Ophthalmic Solution and 4 more · For: Open Angle Glaucoma; Ocular Hypertension
Sites: Dothan, Alabama; Phoenix, Arizona; Garden Grove, California · 25 sites in all
- Reformulated PG324 Ophthalmic Solution for Intraocular Pressure ReductionPivotal-lookingCompleted
Alcon ResearchIndustry
NCT07082816 · 489 participants · Start Sep 2, 2025 · Primary completion Apr 6, 2026
Drug: Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution; Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution · For: Ocular Hypertension; Open Angle Glaucoma
Sites: Dothan, Alabama; Phoenix, Arizona; Garden Grove, California · 30 sites in all
- Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Aerie PharmaceuticalsIndustry
NCT03284853 · 436 participants · Start Sep 5, 2017 · Primary completion Nov 6, 2020
Drug: Netarsudil/Latanoprost 0.02%/0.005%; GANFORT® · For: Open Angle Glaucoma; Ocular Hypertension
Sites: Graz, Austria; Vienna, Austria; Leuven, Belgium · 68 sites in all
- Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Aerie PharmaceuticalsIndustry
NCT02207491 · 411 participants · Start Jul 2014 · Primary completion Mar 2015
Drug: Timolol maleate Ophthalmic Solution 0.5% BID; AR-13324 Ophthalmic Solution 0.02% · For: Ocular Hypertension; Open-angle Glaucoma
Sites: Bedminster, New Jersey
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- conjunctival hyperaemia246
- vision blurred165
- ocular hyperaemia162
- off label use158
- eye pain149
- eye irritation123
- product dose omission issue98
- corneal oedema95
- intraocular pressure increased95
- lacrimation increased94
- visual acuity reduced89
- drug ineffective79
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2018 | 145 |
| 2019 | 470 |
| 2020 | 253 |
| 2021 | 111 |
| 2022 | 137 |
| 2023 | 244 |
| 2024 | 210 |
| 2025 | 227 |
| 2026 | 173 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Rhopressa (Netarsudil Mesylate)
2024 spending
$168M
Beneficiaries
89,311
353,836 claims
Per beneficiary
$1,882
$126.18 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $109,355,175 |
| 2021 | $134,396,762 |
| 2022 | $160,954,924 |
| 2023 | $174,888,744 |
| 2024 | $168,045,637 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension.
Stalmans I, Lim KS, Oddone F, et al. · Graefes Arch Clin Exp Ophthalmol 2024 · Randomized Controlled Trial, Multicenter Study
- Ocular effects of Rho kinase (ROCK) inhibition: a systematic review.
Lin JB, Harris JM, Baldwin G, et al. · Eye (Lond) 2024 · Systematic Review, Research Support, Non-U.S. Gov't
- Netarsudil v/s Ripasudil: The battle of supremacy between two ROCKS-I (rho kinase inhibitors).
Juneja R, Khan T, Gupta VS, et al. · Int Ophthalmol 2025 · Randomized Controlled Trial, Comparative Study
- Phase 3 Clinical Trial Comparing the Safety and Efficacy of Netarsudil to Ripasudil in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Japan Rho Kinase Elevated Intraocular Pressure Treatment Trial (J-ROCKET).
Araie M, Sugiyama K, Aso K, et al. · Adv Ther 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and safety of netarsudil/latanoprost fixed-dose combination vs. monotherapy in open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis of randomized controlled trials.
Luo N, Jiang X, Hao M, et al. · Front Med (Lausanne) 2022 · Systematic Review
- Topical Netarsudil in Childhood Glaucoma: A Systematic Review.
Shaikh O, Kuziez L, Saeedi OJ, et al. · Curr Eye Res 2025 · Systematic Review
Sponsor: Alcon Labs INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.